Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from Brokerages

Key Points

• Quince Therapeutics, Inc. has received a consensus recommendation of "Buy" from twelve rating firms, with an average 12-month target price of $8.14 per share.
• The company's latest earnings report showed an earnings per share of ($0.34), missing estimates by ($0.06), and analysts predict a -1.21 EPS for the current fiscal year.
• Recent institutional investments include a new stake from Ieq Capital valued at approximately $1,073,000 and significant portfolio increases from other hedge funds, indicating strong interest in the company.

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the twelve ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $8.1429.

A number of research analysts have weighed in on the company. D. Boral Capital reaffirmed a "buy" rating and set a $4.00 target price on shares of Quince Therapeutics in a report on Friday, September 26th. Citizens Jmp started coverage on Quince Therapeutics in a report on Tuesday, August 5th. They set a "strong-buy" rating and a $9.00 target price for the company. JMP Securities cut their price objective on Quince Therapeutics from $9.00 to $8.00 and set a "market outperform" rating for the company in a report on Tuesday, August 12th. Zacks Research raised Quince Therapeutics from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 26th. Finally, Citigroup started coverage on Quince Therapeutics in a report on Tuesday, August 5th. They set an "outperform" rating for the company.

Quince Therapeutics Stock Up 0.6%

QNCX stock opened at $1.65 on Friday. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 1.45. The firm has a market capitalization of $88.62 million, a PE ratio of -1.51 and a beta of 1.07. Quince Therapeutics has a twelve month low of $0.69 and a twelve month high of $2.45. The stock has a 50-day simple moving average of $1.63 and a two-hundred day simple moving average of $1.40.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.06). On average, equities analysts predict that Quince Therapeutics will post -1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Two Sigma Investments LP purchased a new position in shares of Quince Therapeutics during the fourth quarter worth about $57,000. Ieq Capital LLC bought a new stake in Quince Therapeutics in the 1st quarter worth approximately $1,073,000. Virtu Financial LLC lifted its position in Quince Therapeutics by 48.4% in the 1st quarter. Virtu Financial LLC now owns 43,332 shares of the company's stock worth $58,000 after buying an additional 14,128 shares during the last quarter. Intellectus Partners LLC bought a new stake in Quince Therapeutics in the 1st quarter worth approximately $71,000. Finally, Nantahala Capital Management LLC bought a new stake in Quince Therapeutics in the 2nd quarter worth approximately $4,172,000. Hedge funds and other institutional investors own 30.75% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.